




Cell-penetrating antagomir for acute myocardial infarction (non-clinical study)

RegenInnopharm Inc

Disease Area	<i>Cardiovascular disease</i>
Product Type	ASO-antagomir
Indication	Acute myocardial infarction
Target	miR 145
Mechanism of Action	Protect myocardium, inhibit inflammation & fibrosis, promote regeneration
Competitiveness	<ul style="list-style-type: none"> Recover heart function (LVEF%) within 4 days after onset to >90% of normal state in pig infarction model. The recovered heart function (>90%) is maintained up to 12 month of FU in pig. Safety(No arrhythmia, no cytokine release storm, no adverse effects at doses 20-40 folds higher than clinical dose) (GLP-DRF) logistics: Lyophilized powder, stable during storage and transport handling Easy use: injected during PCI, no additional process for drug delivery
Development Stage	<i>Pre-clinical</i>
Route of Administration	Intra-coronary artery (during PCI)
Key Data	<p>>90% recovery of LVEF within 4 days of post-MI and long-term maintenance</p>  <p>Inhibition of fibrotic Remodeling after MI</p>  <p>No ventricular arrhythmia (28 days F-U)</p> 
IP	Patent pending in USA, EU, China, Japan